Teva Pharmaceutical Industries Limited (TEVA) Study Finds Gaps in Tardive Dyskinesia Care at Long-Term Facilities

A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and treatment of tardive dyskinesia (TD) among residents in long-term care (LTC) facilities. The research, presented today at Psych Congress Elevate, shows that over half of LTC residents with TD are not receiving the standard-of-care treatment, and 25% are left untreated altogether.

A manufacturer packaging eyecare products in a factory.

The study highlights that many LTC residents are misdiagnosed with the broader category of extrapyramidal syndrome (EPS), leading to inappropriate or insufficient treatment for TD. Only 1.1% of residents on antipsychotic drugs (APDs) had a specific TD diagnosis, while 5.6% were labeled with EPS. Most patients at risk for TD had comorbidities like dementia and heart failure.

Less than half of diagnosed TD patients received recommended VMAT2 inhibitor therapy; most were given non-FDA-approved drugs such as benztropine. Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s leadership emphasizes the urgent need for accurate diagnosis and timely intervention in LTC settings. Teva Pharmaceutical Industries Limited (NYSE:TEVA) pledges ongoing research to address these critical gaps and improve care for patients living with TD.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.